皮下注射5-氮杂胞苷（NSC-102816）治疗转移性恶性黑色素瘤患者的II期研究。
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
作者信息
Bellet R E, Catalano R B, Mastrangelo M J, Berd D
出版信息
Med Pediatr Oncol. 1978;4(1):11-5. doi: 10.1002/mpo.2950040104.
PMID:75498
Abstract
Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC-45388) and a nitrosourea were treated with 5-azacytidine (NSC-102816). 5-Azacytidine was administered subcutaneously at a dosage of 100 mg/m2/day for 10 days. Twenty-six (26) patients were evaluable for toxicity and response. Major organ toxicities were hematologic, gastrointestinal, and cutaneous; no antitumor activity was noted.
摘要
30例对达卡巴嗪（NSC-45388）和一种亚硝基脲耐药的晚期转移性恶性黑色素瘤患者接受了5-氮杂胞苷（NSC-102816）治疗。5-氮杂胞苷以100 mg/m²/天的剂量皮下注射，共10天。26例患者可评估毒性和反应。主要器官毒性为血液学、胃肠道和皮肤毒性；未观察到抗肿瘤活性。
Zotero 插件